Evidence mapPaperPMID 41127192Full record

ReviewRSC advances2025

A bibliometric review of triazine hybrids: synthesis, reactions, and applications spanning the last quarter-century (2000-2025).

Hajar A Ali, Mohamed A Ismail, Eslam A Ghaith

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Synthesis and crystal structure of 4,6-di-amino-1-cyclo-hexyl-1,3,5-triazine-2(1Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hajar A AliChemistry Department, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt abdelghaffar@mans.edu.eg +201024410784.
Mohamed A IsmailChemistry Department, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt abdelghaffar@mans.edu.eg +201024410784.
Eslam A GhaithChemistry Department, Faculty of Science, Mansoura University El-Gomhoria Street Mansoura 35516 Egypt abdelghaffar@mans.edu.eg +201024410784.ORCID https://orcid.org/0000-0003-4259-6802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This comprehensive review delves into the intricate world of triazines, including their structures and the chemical diversity of their isomers. Additionally, this report encompasses a wide range of synthetic approaches, describing numerous reactions for attaining triazines, such as Bamberger, Bischler, inverse-electron-demand Diels-Alder, and Diels-Alder reactions. Moreover, this review describes the progress made in the chemistry of triazines, which is organized based on their reaction types, spotlighting the recent development. Accordingly, triazines stand out as a transformative strategy in the progress of synthetic chemistry due to their diverse applications in medicine, pharmacy, industry, and agriculture. Besides, triazine hybrids are important pharmacophores in the development of medications due to their captivating biological efficacy and biocompatibility. Consequently, this review presents a vast number of marketed drugs containing a triazine template while delineating their molecular mechanisms of action in disrupting disease pathways. Moreover, triazine cores are highlighted as flexible platforms for constructing and fine-tuning metal complexes and catalytic ligands in the period from 2000 to mid-2025. We anticipate that this review will be valuable to researchers focusing on the structural design and advancement of triazines.

Identifiers

PMID41127192
PMCPMC12538292

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.